After Endo (ENDP) received approval for Corphedra, the second FDA approved formulation of ephedrine after Avadel Pharmaceuticals' (AVDL), Jefferies analyst David Steinberg says new product approvals are now even more critical to Akorn's (AKRX) 2017 outlook and share price. Both Endo and Avadel will compete with Akorn's largest product, Steinberg tells investors in a research note. His model assumes Akorn's ephedrine sales will decline to $80M in FY17 from $230M in FY16. The analyst keeps a Buy rating on Akorn, however, saying the shares look "very inexpensive" on "multiple valuation metrics."